spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Myobloc 

 HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Oct 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Feb 2016
Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Oct 2013
FDA Approves JUVÉDERM VOLUMA(TM) XC
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 6 May 2010
Dicerna Names Douglas Fambrough as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Feb 2008
Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2007
Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2007
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 15 May 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2006
Solstice Neurosciences Raises $85 Million in Private Financing
Biopharmaceuticals Venture Capital
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
Myobloc
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.